公开(公告)号：US12098133B2

公开(公告)日：2024-09-24

申请号：US18075316

申请日：2022-12-05

申请人： CV6 Therapeutics (NI) Limited

发明人： Mark Spyvee ,  Pravin S. Shirude

IPC分类号： C07D233/74 ,  A61K31/4015 ,  A61P35/00 ,  C07D207/36 ,  C07D207/40 ,  C07D207/404 ,  C07D211/88 ,  C07D233/46 ,  C07D239/22 ,  C07D241/08 ,  C07D249/12 ,  C07D251/10 ,  C07D263/44 ,  C07D277/34 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D487/04 ,  C07F9/6506

CPC分类号： C07D233/74 ,  A61K31/4015 ,  A61P35/00 ,  C07D207/36 ,  C07D207/40 ,  C07D207/404 ,  C07D211/88 ,  C07D233/46 ,  C07D239/22 ,  C07D241/08 ,  C07D249/12 ,  C07D251/10 ,  C07D263/44 ,  C07D277/34 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D487/04 ,  C07F9/6506

摘要： Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

公开(公告)号：US20220313826A1

公开(公告)日：2022-10-06

申请号：US17107781

申请日：2020-11-30

申请人： C4 Therapeutics, Inc.

发明人： Andrew J. Phillips ,  Christopher G. Nasveschuk ,  James A. Henderson ,  Yanke Liang ,  Minsheng He ,  Kiel Lazarski ,  Gesine Kerstin Veits ,  Harit U. Vora

IPC分类号： A61K47/54 ,  C07D401/14 ,  C07D413/04 ,  C07D221/22 ,  C07D401/12 ,  C07D401/06 ,  C07D401/04 ,  C07D495/04 ,  C07D471/08 ,  C07D487/04 ,  C07D211/86 ,  C07D495/14 ,  C07D413/14 ,  C07D417/14 ,  C07D211/90 ,  C07D519/00 ,  C07D405/14 ,  C07D417/04 ,  C07D471/04 ,  C07D211/88 ,  A61K31/45 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4545

摘要： This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

公开(公告)号：US20210155592A1

公开(公告)日：2021-05-27

申请号：US17164204

申请日：2021-02-01

申请人： California Institute of Technology

发明人： Brian M. Stoltz ,  Scott C. Virgil ,  David E. White ,  Taiga Yurino ,  Yiyang Liu ,  Douglas C. Behenna ,  Douglas Duquette ,  Christian Eidamshaus

IPC分类号： C07D211/78 ,  C07D265/32 ,  C07D211/60 ,  C07D207/16 ,  C07D223/10 ,  C07D309/04 ,  C07D223/04 ,  C07D241/04 ,  C07D241/08 ,  C07D241/52 ,  C07D207/06 ,  C07D265/30 ,  C07D207/08 ,  C07D207/10 ,  C07D207/26 ,  C07D207/263 ,  C07D207/27 ,  C07D207/46 ,  C07D211/16 ,  C07D211/18 ,  C07D211/22 ,  C07D211/34 ,  C07D211/38 ,  C07D211/76 ,  C07D211/88 ,  C07D211/94 ,  C07D211/96 ,  C07D309/30 ,  C07D207/267 ,  C07D207/273 ,  C07D207/277 ,  C07D211/90

摘要： The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): comprising treating a compound of Formula (I): with a transition metal catalyst and under alkylation conditions as valence and stability permit.

公开(公告)号：US10849982B2

公开(公告)日：2020-12-01

申请号：US16186341

申请日：2018-11-09

申请人： C4 Therapeutics, Inc.

发明人： Andrew J. Phillips ,  Chris G. Nasveschuk ,  James A. Henderson ,  Yanke Liang ,  Minsheng He ,  Kiel Lazarski ,  Gesine Kerstin Veits ,  Harit U. Vora

IPC分类号： A61K47/54 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/519 ,  C07D401/14 ,  C07D413/04 ,  C07D221/22 ,  C07D401/12 ,  C07D401/06 ,  C07D401/04 ,  C07D495/04 ,  C07D471/08 ,  C07D487/04 ,  C07D211/86 ,  C07D495/14 ,  C07D413/14 ,  C07D417/14 ,  C07D211/90 ,  C07D519/00 ,  C07D405/14 ,  C07D417/04 ,  C07D471/04 ,  C07D211/88 ,  A61K31/45 ,  A61K31/451 ,  A61K31/454 ,  C07K14/47 ,  C07K14/72

摘要： This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

公开(公告)号：US20200325105A1

公开(公告)日：2020-10-15

申请号：US16799785

申请日：2020-02-24

申请人： University of Southern California ,  CV6 Therapeutics (NI) Limited

发明人： Robert D. Ladner ,  Mark Spyvee ,  Pravin S. Shirude

IPC分类号： C07D241/08 ,  C07D213/74 ,  C07D233/74 ,  C07D239/22 ,  C07D207/416 ,  C07D211/88 ,  C07D207/40 ,  A61P35/02

摘要： Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

公开(公告)号：US20200283394A1

公开(公告)日：2020-09-10

申请号：US16773411

申请日：2020-01-27

申请人： CV6 Therapeutics (NI) Limited

发明人： Mark Spyvee ,  Pravin S. Shirude

IPC分类号： C07D239/22 ,  C07D211/88 ,  C07D207/404 ,  A61K31/513 ,  A61P35/00

摘要： Provided herein are dUTPase inhibitors of Formula (I), compositions comprising such compounds and methods of using such compounds and compositions

公开(公告)号：US20200270207A1

公开(公告)日：2020-08-27

申请号：US16806115

申请日：2020-03-02

申请人： University of Southern California ,  CV6 Therapeutics (NI) Limited

发明人： Robert D. Ladner ,  Mark Spyvee ,  Pravin S. Shirude

IPC分类号： C07D207/40 ,  C07D239/22 ,  C07D277/34 ,  C07D211/88 ,  C07D251/20 ,  C07D241/08 ,  A61P35/00 ,  C12Q1/6886

摘要： Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

公开(公告)号：US20190270756A1

公开(公告)日：2019-09-05

申请号：US16462153

申请日：2017-11-21

申请人： CV6 Therapeutics (NI) Limited

发明人： Mark Spyvee ,  Michael Lewis

IPC分类号： C07D498/04 ,  C07D239/22 ,  C07D241/18 ,  C07D211/88 ,  C07D401/12 ,  C07D251/20 ,  C07D251/30 ,  C07D213/79 ,  C07D213/69 ,  C07D239/54 ,  C07D237/16 ,  C07D239/14 ,  C07D413/06 ,  C07D401/06 ,  C07D401/14 ,  C07D471/04 ,  C07D403/06 ,  A61P35/00

摘要： Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

公开(公告)号：US10343996B2

公开(公告)日：2019-07-09

申请号：US16049434

申请日：2018-07-30

申请人： California Institute of Technology

发明人： Brian M. Stoltz ,  Scott C. Virgil ,  David E. White ,  Taiga Yurino ,  Yiyang Liu ,  Douglas C. Behenna ,  Douglas Duquette ,  Christian Eidamshaus

IPC分类号： C07D211/78 ,  C07D211/16 ,  C07D211/18 ,  C07D211/22 ,  C07D211/34 ,  C07D211/38 ,  C07D211/60 ,  C07D211/76 ,  C07D211/88 ,  C07D211/90 ,  C07D211/94 ,  C07D211/96 ,  C07D207/06 ,  C07D207/08 ,  C07D207/10 ,  C07D207/16 ,  C07D207/26 ,  C07D207/263 ,  C07D207/267 ,  C07D207/27 ,  C07D207/273 ,  C07D207/277 ,  C07D207/46 ,  C07D223/04 ,  C07D223/10 ,  C07D241/04 ,  C07D241/08 ,  C07D265/30 ,  C07D265/32 ,  C07D309/04 ,  C07D309/30 ,  C07D241/52

摘要： The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): comprising treating a compound of Formula (I): with a transition metal catalyst and under alkylation conditions as valence and stability permit.

公开(公告)号：US10220029B2

公开(公告)日：2019-03-05

申请号：US15844703

申请日：2017-12-18

申请人： OBSCHESTVO S ORGANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES”

发明人： Vladimir Evgenievich Nebolsin ,  Tatyana Alexandrovna Kromova ,  Anastasia Vladimirovna Rydlovskaya ,  Alexander Grigorievich Chuchalin

IPC分类号： A61K31/454 ,  C07D211/88

摘要： The present invention relates to novel biologically active glutarimide derivatives of general formula (I) or a pharmaceutically acceptable salt thereof, their use as a therapeutic agent for the treatment of eosinophilic diseases, preferably of allergic nature, in particular bronchial asthma, allergic rhinitis, polypous rhinosinusopathies, eosinophilic colitis, eosinophilic syndrome, allergic conjunctivitis, atopic dermatitis, Churg-Strauss syndrome, anaphylactic shock, Quincke's edema, eosinophilic vasculitis, eosinophilic esophagitis, eosinophilic gastroenteritis, or fibroses. The invention also relates to pharmaceutical compositions comprising glutarimide derivatives of general formula (I):